VUNO, "Looking into the Brain"... 'DeepBrain' Ahead of US Entry, Patent Registered

Medical AI company VUNO announced on the 30th that two core technology patents related to its AI-based brain quantification medical device, VUNO Med-DeepBrain, which was officially launched recently in the United States, have been granted patent registration in the US. The two patents registered in the US are technologies that enhance the efficiency of deep learning-based brain magnetic resonance imaging (MRI) analysis and suggest various potential applications.

Vuno's 'Vuno Med DeepBrain' image [Photo by Vuno]

First, the "Machine learning method of neural networks for predicting drug mechanisms of action and method for predicting drug mechanisms of action using neural networks" is a technology used to periodically monitor the efficacy of drugs related to various brain diseases in brain MRI images based on deep learning. Time-series brain MRI images used to verify the effects of drugs in various brain diseases, including mental disorders, are large in size, making it difficult to train or utilize deep learning models for analysis.

VUNO's technology extracts compressed data from time-series brain MRI images to reduce the size, enabling deep learning models to help predict the drug's mechanism of action at specific future time points. It can also be used to observe changes in side effects that may occur when using recently introduced Alzheimer's disease treatments and to predict prognosis.

The "Disease prediction method based on medical imaging" is a technology that processes three-dimensional brain MRI images to facilitate deep learning analysis. Three-dimensional MRI images are used to determine whether diseases that can cause Alzheimer's disease or other dementias are present, but due to the large amount and complexity of information, deep learning model computations consume significant time and computing resources. Therefore, three-dimensional medical images are reconstructed into two-dimensional medical images, which are then input into deep learning models to predict diseases or confirm the presence of onset.

VUNO plans to accelerate the entry of VUNO Med-DeepBrain, which incorporates these patented technologies, into the US market. VUNO has officially launched the product in the US market through the Alzheimer's Association International Conference (AAIC), the world's largest global conference in the Alzheimer's field currently being held in the US. In the second half of this year, VUNO intends to establish a local sales network in earnest and pursue entry into the US healthcare insurance system.

Lee Ye-ha, CEO of VUNO, said, "The patents registered this time are core technologies that improve the efficiency of brain MRI analysis based on AI and suggest various clinical applications such as predicting the effects of dementia treatments. We will strategically approach the US market, where early entry is crucial, to successfully establish a foothold and continue efforts to ensure that this product can contribute to solving dementia issues in more medical settings."

This content was produced with the assistance of AI translation services.